Sign in / Join Now
ETFs & Funds
came out with great data on sapacitabine for
. Not only does it work well, but it also an ORAL med. Wall St ignoring good data again
Looks like they are listening today. Too late to buy some?
Add a reply...
Latest StockTalks »
people get CYCC breaking news and analysis by email alert.
Get email alerts on CYCC »
Cyclacel Pharmaceuticals, Inc.
Get latest price
From other sites
Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia
at TheStreet (Dec 1, 2016)
Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results
at TheStreet (Nov 14, 2016)
Cyclacel Pharmaceuticals's Preferred Stock Shares Cross 9% Yield Mark
at TheStreet (Nov 8, 2016)
Cyclacel Pharmaceuticals To Release Third Quarter 2016 Financial Results
at TheStreet (Nov 7, 2016)
Cyclacel's CYC065 Demonstrates Promising Activity In MYCN-Addicted Neuroblastoma In Preclinical Data Presented At Childhood Cancer 2016
at TheStreet (Sep 6, 2016)